Combination of ascorbate/epigallocatechin-3-gallate/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells

Toxicology and Applied Pharmacology

Volumn 274, Issue 1, 2014, Pages 35-41

  Martinotti, Simona ^a   Ranzato, Elia ^a   Parodi, Monica ^b,c   Vitale, Massimo ^b   Burlando, Bruno ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Cell cycle; Combined therapy; DAPK2; PCR array; REN mesothelioma cells

Indexed keywords

ASCORBIC ACID; CALCIUM; CASPASE 3; DEATH ASSOCIATED PROTEIN KINASE; EPIGALLOCATECHIN GALLATE; GEMCITABINE; LIPOCORTIN 5;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOSOL; DNA CONTENT; DOWN REGULATION; DRUG POTENTIATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IC 50; MALIGNANT MESOTHELIOMA; POLYMERASE CHAIN REACTION; PROMOTER REGION; UPREGULATION; WESTERN BLOTTING;

EID: 84889596580     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.10.025     Document Type: Article

References (35)

1. Martino D., Pass H.I. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004, 5:290-298.
2. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., Legrand C., Bottomley A., Debruyne C., Giaccone G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005, 23:6881-6889.
3. Kindler H.L., van Meerbeeck J.P. The role of gemcitabine in the treatment of malignant mesothelioma. Semin. Oncol. 2002, 29:70-76.
4. Sarkar F.H., Li Y.W. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol. Sin. 2007, 28:1305-1315.
5. Neoptolemos J.P., Cunningham D., Friess H., Bassi C., Stocken D.D., Tait D.M., Dunn J.A., Dervenis C., Lacaine F., Hickey H., Raraty M.G., Ghaneh P., Buchler M.W. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann. Oncol. 2003, 14:675-692.
6. Ohno S., Ohno Y., Suzuki N., Soma G., Inoue M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res. 2009, 29:809-815.
7. Ranzato E., Biffo S., Burlando B. Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism. Am. J. Respir. Cell Mol. Biol. 2011, 44:108-117.
8. Martinotti S., Ranzato E., Burlando B. In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol. in Vitro 2011, 25:1568-1574.
9. Volta V., Ranzato E., Martinotti S., Gallo S., Russo M.V., Mutti L., Biffo S., Burlando B. Preclinical demonstration of synergistic active nutrients/drug (AND) combination as a potential treatment for malignant pleural mesothelioma. PLoS One 2013, 8:e58051.
10. Gupta S., Hastak K., Afaq F., Ahmad N., Mukhtar H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 2004, 23:2507-2522.
11. Ranzato E., Martinotti S., Magnelli V., Murer B., Biffo S., Mutti L., Burlando B. Epigallocatechin-3-gallate induces mesothelioma cell death via H(2)O(2)-dependent T-type Ca(2+) channel opening. J. Cell. Mol. Med. 2012, 6(11):2667-2678.
12. Bertino P., Piccardi F., Porta C., Favoni R., Cilli M., Mutti L., Gaudino G. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin. Cancer Res. 2008, 14:541-548.
13. Smythe W.R., Hwang H.C., Amin K.M., Eck S.L., Davidson B.L., Wilson J.M., Kaiser L.R., Albelda S.M. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 1994, 54:2055-2059.
14. Ranzato E., Grosso S., Patrone M., Betta P.G., Viarengo A., Biffo S. Spreading of mesothelioma cells is rapamycin-sensitive and requires continuing translation. J. Cell. Biochem. 2009, 108:867-876.
15. Kawai T., Nomura F., Hoshino K., Copeland N.G., Gilbert D.J., Jenkins N.A., Akira S. Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity. Oncogene 1999, 18:3471-3480.
16. Tur M.K., Neef I., Jost E., Galm O., Jager G., Stocker M., Ribbert M., Osieka R., Klinge U., Barth S. Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J. Immunother. 2009, 32:431-441.
17. Britschgi A., Simon H.U., Tobler A., Fey M.F., Tschan M.P. Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2. Br. J. Haematol. 2010, 149:55-64.
18. Giroux V., Iovanna J., Dagorn J.C. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J. 2006, 20:1982-1991.
19. Shammas MA M.A., Neri P., Koley H., Batchu R.B., Bertheau R.C., Munshi V., Prabhala R., Fulciniti M., Tai Y.T., Treon S.P., Goyal R.K., Anderson K.C., Munshi N.C. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006, 108:2804-2810.
20. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684.
21. Hernandez-Vargas H., Rodriguez-Pinilla S.M., Julian-Tendero M., Sanchez-Rovira P., Cuevas C., Anton A., Rios M.J., Palacios J., Moreno-Bueno G. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res. Treat. 2007, 102:157-172.
22. Krakauer T. Nuclear factor-kappaB: fine-tuning a central integrator of diverse biologic stimuli. Int. Rev. Immunol. 2008, 27:286-292.
23. Verstrepen L., Verhelst K., van Loo G., Carpentier I., Ley S.C., Beyaert R. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem. Pharmacol. 2010, 80:2009-2020.
24. Li Q., Sato E.F., Zhu X., Inoue M. A simultaneous release of SOD1 with cytochrome c regulates mitochondria-dependent apoptosis. Mol. Cell. Biochem. 2009, 322:151-159.
25. Price J., Zaidi A.K., Bohensky J., Srinivas V., Shapiro I.M., Ali H. Akt-1 mediates survival of chondrocytes from endoplasmic reticulum-induced stress. J. Cell. Physiol. 2010, 222:502-508.
26. Magyar J.E., Gamberucci A., Konta L., Margittai E., Mandl J., Banhegyi G., Benedetti A., Csala M. Endoplasmic reticulum stress underlying the pro-apoptotic effect of epigallocatechin gallate in mouse hepatoma cells. Int. J. Biochem. Cell Biol. 2009, 41:694-700.
27. Portt L., Norman G., Clapp C., Greenwood M., Greenwood M.T. Anti-apoptosis and cell survival: a review. Biochim. Biophys. Acta 2011, 1813:238-259.
28. Banerjee S., Manna S., Mukherjee S., Pal D., Panda C.K., Das S. Black tea polyphenols restrict benzopyrene-induced mouse lung cancer progression through inhibition of Cox-2 and induction of caspase-3 expression. Asian Pac. J. Cancer Prev. 2006, 7:661-666.
29. Sarkar S.A., Kutlu B., Velmurugan K., Kizaka-Kondoh S., Lee C.E., Wong R., Valentine A., Davidson H.W., Hutton J.C., Pugazhenthi S. Cytokine-mediated induction of anti-apoptotic genes that are linked to nuclear factor kappa-B (NF-kappaB) signalling in human islets and in a mouse beta cell line. Diabetologia 2009, 52:1092-1101.
30. Shinkaruk S., Bayle M., Lain G., Deleris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents 2003, 3:95-117.
31. Morgan M.A., Parsels L.A., Maybaum J., Lawrence T.S. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clinical cancer research. Off. J. Am. Assoc. Cancer Res. 2008, 14:6744-6750.
32. Shaulian E., Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400.
33. Marlowe J.L., Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J. Cell. Biochem. 2005, 96:1174-1184.
34. Pusapati R.V., Weaks R.L., Rounbehler R.J., McArthur M.J., Johnson D.G. E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol. Carcinog. 2010, 49:152-156.
35. Wichmann A., Uyetake L., Su T.T. E2F1 and E2F2 have opposite effects on radiation-induced p53-independent apoptosis in Drosophila. Dev. Biol. 2010, 346:80-89.